Bio-manufacturing research and development through a capital and business alliance with フェルメクテス
First written in FY2024. 1 of 2 entries say "Advanced", first in FY2025-H1. Latest entry: FY2025-H1.
No other company in this theme has enough history to compare yet.
- FY2025-H1AdvancedAnnual report
「We have subscribed for 14,000 common shares issued by フェルメクテス. フェルメクテス is a company working on the “development of foods made primarily from natto bacteria.” We are conducting collaborative research primarily aimed at improving yields to reduce manufacturing costs in “biomanufacturing,” using metabolome data generated through our strength in metabolomics technology and related metabolic analyses based on that data.」
The subscription for 14,000 common shares under the capital and business alliance with フェルメクテス has been completed, and joint research on biomanufacturing using metabolomics technology is under way. - FY2024First statedAnnual report
「フェルメクテス is a company working on the “development of foods made primarily from natto bacteria.” We have entered into a collaborative research arrangement primarily aimed at improving yields to reduce manufacturing costs in “biomanufacturing,” using metabolome data generated through our strength in metabolomics technology and related metabolic analyses based on that data.」
On 11 September 2024, we resolved to enter into a capital and business alliance with フェルメクテス and planned to subscribe for 14,000 common shares for ¥49.98 million. We will conduct joint research using metabolomics technology to improve the yield and reduce the manufacturing costs of foods derived from natto bacteria.